MedTrace Logo

ESBA1008 Safety, Tolerability and Effects in Wet Age-Related Macular Degeneration (AMD) Patients

NCT01304693 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 376

Last updated 2014-07-17

Study results available
· View outcomes & findings →

Summary

The purpose of this study was to assess the safety, tolerability, and the effects of treatment on ocular outcomes following a single intravitreal administration of ESBA1008 compared with LUCENTIS® in patients with exudative age-related macular degeneration (AMD).

Conditions

  • Exudative Age-Related Macular Degeneration

Interventions

BIOLOGICAL

ESBA1008 solution

Administered as a single intravitreal injection (Dose A, Dose B, Dose C, Dose D)

BIOLOGICAL

Ranibizumab 0.5 mg

Administered as a single intravitreal injection

Sponsors & Collaborators

  • Alcon Research

    lead INDUSTRY

Principal Investigators

  • Georges Weissgerber, MD · Alcon Research

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-10-31
Primary Completion
2013-03-31
Completion
2013-03-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01304693 on ClinicalTrials.gov